InsidersTradesSigma
Total declarations
Companies
▲ Purchases (1 ops.)
▼ Sales (0 ops.)
Insider track record
Board DirectorDisclosed buys
1
Disclosed sells
0
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Explore the full record of transactions filed by Nussbaum Ran, Director. Officer active across 4 companies, notably Eloxx Pharmaceuticals, Inc.. Cumulatively, 11 filings have been recorded. Breakdown: 1 buy · 0 sell. Total volume traded: €1.4m. History available since 13 May 2021. The latest transaction was filed on 4 June 2025 (Attribution). Regulator: SEC (Form 4). All data is openly available.
Companies and markets linked to Nussbaum Ran
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations11 total
411,681 sharesCommon StockSEC:0001609805-25-000006:0
5,250 shares0Common StockSEC:0001415889-25-015976:0
47,999 shares@ US$5.9446.2% of flowOrdinary SharesSEC:0001437749-23-004868:0
1,030 shares@ US$5.000.8% of flowOrdinary SharesSEC:0001437749-23-004870:0
2,211 shares@ US$5.001.7% of flowOrdinary SharesSEC:0001437749-23-004866:0
3,539 shares100.0% of flowCommon StockSEC:0001209191-22-059052:0
47,999 shares@ US$5.9446.2% of flowOrdinary SharesSEC:0001437749-22-024711:0
1,030 shares@ US$5.000.8% of flowOrdinary SharesSEC:0001437749-22-021338:0
2,211 shares@ US$5.002.9% of flowOrdinary SharesSEC:0001209191-21-039132:0
1,030 shares@ US$5.001.4% of flowOrdinary SharesSEC:0001209191-21-039137:0
1,280,624 shares@ US$1.35100.0% of flowCommon StockSEC:0001104659-21-067335:0
Canonical exit: 11 Aug 2021 (T+90)
11 of 11 declarations
About Nussbaum Ran
Ran Nussbaum is a Board Member at Eloxx Pharmaceuticals, Inc. and UroGen Pharma Ltd. He is responsible for overseeing the operations and strategy of these companies. His experience in the pharmaceutical sector allows him to make significant contributions to strategic discussions. As a board member, he ensures that decisions made align with the growth and innovation objectives of the companies.
